Fig. 3From: Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohortImpact of gender on response to secukinumab. a) Percentages of male and female patients with AS or PsA achieving different outcomes at 52 weeks of treatment. CII, clinically important improvement. *P < 0.05 (males vs. females). b) Kaplan-Meier drug survival curves of male and female patients during one year of follow-up. c) Percentages (and numbers) of male and female patients who experienced poor outcomes during follow-up (i.e., primary and secondary failures or suboptimal responses accounting for subsequent drug discontinuation), in the whole cohort and separately in the AS and PsA groups.Back to article page